+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Aptamers Market Size, Share & Trends Analysis Report By Type (Nucleic Acid, Peptide), By Application (Diagnostics, Therapeutics, Research & Developments, Others), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830937
The global aptamers market size is expected to reach USD 10.88 billion by 2030. The market is expected to expand at a CAGR of 24.54% from 2023 to 2030. The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer, solid tumors, and renal cancer.

In addition, initiatives undertaken by regulatory agencies such as the U. S. FDA, Health Canada, EMA, COFEPRIS, MHRA, and CDSCO to support the research and development in the field of aptamers are projected to fuel market growth. For instance, in March 2020, IVERIC Bio, Inc. received Fast Track designation from the U. S. FDA for Zimura for the treatment of patients with GA secondary to age-related macular degeneration (AMD). Zimura is a chemically synthesized pegylated RNA aptamer, administered by intravitreal injection. It acts by inhibiting complement factor C5 which is responsible for the development of AMD.

Companies are studying aptamers for applications such as western blotting, ELISA, therapeutics, and flow cytometry. Custom aptamer selection is considered to be an important service offered by existing aptamer players to life sciences companies. Thrombin aptamers, cocaine aptamers, and theophylline aptamers are some of the most frequently used customized aptamers for research and development activities. Thus, the surge in numbers of biotech and pharma companies working on research related to aptamers and related technologies has opened up new avenues for the growth of this market.

Moreover, there are a number of strategic initiatives undertaken by key players such as mergers & acquisitions, with an aim to expand their current aptamer product portfolio. For instance, in May 2022, Epicore Biosystems acquired Eccrine Systems' intellectual property and assets. This acquisition boosts Epicore’s wearable microfluidic solutions with additional aptamer-based sweat sensor technology from the Eccrine Systems and the University of Cincinnati to its aptamer product portfolio and strengthens the company’s position in the market. This aptamers-based sensor has been demonstrated in stress, pain, and other healthcare management applications.

Aptamers Market Report Highlights

  • The nucleic acid aptamers segment dominated the market in 2022. The segment is set to grow at a rapid pace into areas such as therapeutics, diagnostics, research and development consumables, and biomarker discovery
  • The research and development segment dominated the market in 2022 due to the growing interest of companies in aptamers; moreover, the rising awareness level coupled with favorable government initiatives are expected to stimulate the market growth of this applications segment during the study period
  • The diagnostics segment is expected to be the fastest-growing segment during the forecast period due to the rising demand for aptamer-based diagnostic kits for the early diagnosis of diseases. For instance, in July 2021, SomaLogic and the CM Life Sciences announced the supply of 7,000-plex SomaScan Assay kits & SomaScan data to Beth Israel Deaconess Medical Center (BIDMC) for proteomics research
  • North America dominated the market in 2022 due to the presence of key biopharmaceutical companies such as SomaLogic, IVERIC Bio, Inc., Aptagen LLC, Base Pair Biotechnologies, and their strategic initiatives for the development of new aptamers


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. High Advantage Of Aptamers Compared To Antibodies
3.2.1.2. Advancements In The Field Of Aptamer Development Technologies
3.2.1.3. Growing Interest Of Many Companies To Invest In Aptamers Market
3.2.1.4. Promising Pipeline Thearpeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Rising Number Of Setbacks Of Aptamer Therapeutics In Late Stage Clinical Studies
3.2.2.2. Low Awareness Level And Incomplete Regulatory Policies Slow Down The Market Growth
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Aptamers Market: Type Movement Analysis
4.2. Nucleic Acid Aptamer
4.2.1. Nucleic Acid Aptamer Market, 2018 - 2030 (USD Million)
4.3. Peptide Aptamer
4.3.1. Peptide Aptamer Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Aptamers Market: Application Movement Analysis
5.2. Diagnostics
5.2.1. Diagnostics Market, 2018 - 2030 (USD Million)
5.3. Therapeutics
5.3.1. Therapeutics Market, 2018 - 2030 (USD Million)
5.4. Research and Development
5.4.1. Research and Development Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Other Applications Market, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Aptamers Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. SWOT Analysis
6.2.2. North America Aptamers Market, 2018 - 2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. U.S. Aptamers Market, 2018 - 2030 (USD Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Canada Aptamers Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. SWOT Analysis
6.3.2. Europe Aptamers Market, 2018 - 2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. UK Aptamers Market, 2018 - 2030 (USD Million)
6.3.4. Germany
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Germany Aptamers Market, 2018 - 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. France Aptamers Market, 2018 - 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Italy Aptamers Market, 2018 - 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Spain Aptamers Market, 2018 - 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Denmark Aptamers Market, 2018 - 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Sweden Aptamers Market, 2018 - 2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Norway Aptamers Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. SWOT Analysis
6.4.2. Asia Pacific Aptamers Market, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Japan Aptamers Market, 2018 - 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. China Aptamers Market, 2018 - 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. India Aptamers Market, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Australia Aptamers Market, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Thailand Aptamers Market, 2018 - 2030 (USD Million)
6.4.8. South Korea
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. South Korea Aptamers Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America Aptamers Market, 2018 - 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Brazil Aptamers Market, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Mexico Aptamers Market, 2018 - 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Argentina Aptamers Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA Aptamers Market, 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. South Africa Aptamers Market, 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Saudi Arabia Aptamers Market, 2018 - 2030 (USD Million)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. UAE Aptamers Market, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Kuwait Aptamers Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2022
7.4. Company Profiles/Listing
7.4.1. SomaLogic
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Aptamer Group
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Aptadel Therapeutics
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Base Pair Biotechnologies
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Noxxon Pharma
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Aptagen, LLC
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Vivonics Inc.
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. TriLink Biotechnologies
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Altermune LLC
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. AM Biotechnologies
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global aptamers market, by type, 2018 - 2030 (USD Million)
Table 3 Global aptamers market, by application, 2018 - 2030 (USD Million)
Table 4 Global aptamers market, by region, 2018 - 2030 (USD Million)
Table 5 North America aptamers market, by country, 2018 - 2030 (USD Million)
Table 6 North America aptamers market, by type, 2018 - 2030 (USD Million)
Table 7 North America aptamers market, by application, 2018 - 2030 (USD Million)
Table 8 U.S. aptamers market, by type, 2018 - 2030 (USD Million)
Table 9 U.S. aptamers market, by application, 2018 - 2030 (USD Million)
Table 10 Canada aptamers market, by type, 2018 - 2030 (USD Million)
Table 11 Canada aptamers market, by application, 2018 - 2030 (USD Million)
Table 12 Europe aptamers market, by country, 2018 - 2030 (USD Million)
Table 13 Europe aptamers market, by type, 2018 - 2030 (USD Million)
Table 14 Europe aptamers market, by application, 2018 - 2030 (USD Million)
Table 15 UK aptamers market, by type, 2018 - 2030 (USD Million)
Table 16 UK aptamers market, by application, 2018 - 2030 (USD Million)
Table 17 Germany aptamers market, by type, 2018 - 2030 (USD Million)
Table 18 Germany aptamers market, by application, 2018 - 2030 (USD Million)
Table 19 France aptamers market, by type, 2018 - 2030 (USD Million)
Table 20 France aptamers market, by application, 2018 - 2030 (USD Million)
Table 21 Italy aptamers market, by type, 2018 - 2030 (USD Million)
Table 22 Italy aptamers market, by application, 2018 - 2030 (USD Million)
Table 23 Spain aptamers market, by type, 2018 - 2030 (USD Million)
Table 24 Spain aptamers market, by application, 2018 - 2030 (USD Million)
Table 25 Denmark aptamers market, by type, 2018 - 2030 (USD Million)
Table 26 Denmark aptamers market, by application, 2018 - 2030 (USD Million)
Table 27 Sweden aptamers market, by type, 2018 - 2030 (USD Million)
Table 28 Sweden aptamers market, by application, 2018 - 2030 (USD Million)
Table 29 Norway aptamers market, by type, 2018 - 2030 (USD Million)
Table 30 Norway aptamers market, by application, 2018 - 2030 (USD Million)
Table 31 Asia Pacific aptamers market, by country, 2018 - 2030 (USD Million)
Table 32 Asia Pacific aptamers market, by type, 2018 - 2030 (USD Million)
Table 33 Asia Pacific aptamers market, by application, 2018 - 2030 (USD Million)
Table 34 Japan aptamers market, by type, 2018 - 2030 (USD Million)
Table 35 Japan aptamers market, by application, 2018 - 2030 (USD Million)
Table 36 China aptamers market, by type, 2018 - 2030 (USD Million)
Table 37 China aptamers market, by application, 2018 - 2030 (USD Million)
Table 38 India aptamers market, by type, 2018 - 2030 (USD Million)
Table 39 India aptamers market, by application, 2018 - 2030 (USD Million)
Table 40 Australia aptamers market, by type, 2018 - 2030 (USD Million)
Table 41 Australia aptamers market, by application, 2018 - 2030 (USD Million)
Table 42 Thailand aptamers market, by type, 2018 - 2030 (USD Million)
Table 43 Thailand aptamers market, by application, 2018 - 2030 (USD Million)
Table 44 South Korea aptamers market, by type, 2018 - 2030 (USD Million)
Table 45 South Korea aptamers market, by application, 2018 - 2030 (USD Million)
Table 46 Latin America aptamers market, by country, 2018 - 2030 (USD Million)
Table 47 Latin America aptamers market, by type, 2018 - 2030 (USD Million)
Table 48 Latin America aptamers market, by application, 2018 - 2030 (USD Million)
Table 49 Brazil aptamers market, by type, 2018 - 2030 (USD Million)
Table 50 Brazil aptamers market, by application, 2018 - 2030 (USD Million)
Table 51 Mexico aptamers market, by type, 2018 - 2030 (USD Million)
Table 52 Mexico aptamers market, by application, 2018 - 2030 (USD Million)
Table 53 Argentina aptamers market, by type, 2018 - 2030 (USD Million)
Table 54 Argentina aptamers market, by application, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa aptamers market, by country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa aptamers market, by type, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa aptamers market, by application, 2018 - 2030 (USD Million)
Table 58 South Africa aptamers market, by type, 2018 - 2030 (USD Million)
Table 59 South Africa aptamers market, by application, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia aptamers market, by type, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia aptamers market, by application, 2018 - 2030 (USD Million)
Table 62 UAE aptamers market, by type, 2018 - 2030 (USD Million)
Table 63 UAE aptamers market, by application, 2018 - 2030 (USD Million)
Table 64 Kuwait aptamers market, by type, 2018 - 2030 (USD Million)
Table 65 Kuwait aptamers market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Aptamers market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 PESTEL analysis
Fig. 13 Porter’s five forces analysis
Fig. 14 Global aptamers market: Type movement analysis
Fig. 15 Global aptamers market, for nucleic acid aptamer, 2018 - 2030 (USD Million)
Fig. 16 Global aptamers market, for peptide aptamer, 2018 - 2030 (USD Million)
Fig. 17 Global aptamers market: Application movement analysis
Fig. 18 Global aptamers market, for diagnostics, 2018 - 2030 (USD Million)
Fig. 19 Global aptamers market, for therapeutics, 2018 - 2030 (USD Million)
Fig. 20 Global aptamers market, for research and development, 2018 - 2030 (USD Million)
Fig. 21 Global aptamers market, for other applications, 2018 - 2030 (USD Million)
Fig. 22 Regional marketplace: Key takeaways
Fig. 23 Regional outlook, 2022 & 2030
Fig. 24 Global aptamers market: Region movement analysis
Fig. 25 North America aptamers market, 2018 - 2030 (USD Million)
Fig. 26 U.S. aptamers market, 2018 - 2030 (USD Million)
Fig. 27 Canada aptamers market, 2018 - 2030 (USD Million)
Fig. 28 Europe aptamers market, 2018 - 2030 (USD Million)
Fig. 29 Germany aptamers market, 2018 - 2030 (USD Million)
Fig. 30 UK aptamers market, 2018 - 2030 (USD Million)
Fig. 31 France aptamers market, 2018 - 2030 (USD Million)
Fig. 32 Italy aptamers market, 2018 - 2030 (USD Million)
Fig. 33 Spain aptamers market, 2018 - 2030 (USD Million)
Fig. 34 Denmark aptamers market, 2018 - 2030 (USD Million)
Fig. 35 Sweden aptamers market, 2018 - 2030 (USD Million)
Fig. 36 Norway aptamers market, 2018 - 2030 (USD Million)
Fig. 37 Asia Pacific aptamers market, 2018 - 2030 (USD Million)
Fig. 38 Japan aptamers market, 2018 - 2030 (USD Million)
Fig. 39 China aptamers market, 2018 - 2030 (USD Million)
Fig. 40 India aptamers market, 2018 - 2030 (USD Million)
Fig. 41 Australia aptamers market, 2018 - 2030 (USD Million)
Fig. 42 South Korea aptamers market, 2018 - 2030 (USD Million)
Fig. 43 Thailand aptamers market, 2018 - 2030 (USD Million)
Fig. 44 Latin America aptamers market, 2018 - 2030 (USD Million)
Fig. 45 Brazil aptamers market, 2018 - 2030 (USD Million)
Fig. 46 Mexico aptamers market, 2018 - 2030 (USD Million)
Fig. 47 Argentina aptamers market, 2018 - 2030 (USD Million)
Fig. 48 Middle East and Africa aptamers market, 2018 - 2030 (USD Million)
Fig. 49 South Africa aptamers market, 2018 - 2030 (USD Million)
Fig. 50 Saudi Arabia aptamers market, 2018 - 2030 (USD Million)
Fig. 51 UAE aptamers market, 2018 - 2030 (USD Million)
Fig. 52 Kuwait aptamers market, 2018 - 2030 (USD Million)

Companies Mentioned

  • SomaLogic
  • Aptamer Group
  • Aptadel Therapeutics
  • Base Pair Biotechnologies
  • Noxxon Pharma
  • Aptagen, LLC
  • Vivonics Inc.
  • TriLink Biotechnologies
  • Altermune LLC
  • AM Biotechnologies

Methodology

Loading
LOADING...

Table Information